Open Payments

Valley Childrens Hospital

Type
Teaching hospital
Where
Madera, CA
Medicare CCN
053300
Received
$194,706 in 89 records, 2021 ($1,688 general, $193,017 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2021General payment49$1,688
2021Research payment40$193,017

By company

CompanyRecordsAmountYears
VERTEX PHARMACEUTICALS INCORPORATED1$86,5542021
Gilead Sciences, Inc.6$59,2252021
PFIZER INC.3$19,5842021
Abbott Laboratories5$8,2902021
Novo Nordisk AS4$7,1452021
Novartis Gene Therapies, Inc. (fka Avexis, Inc.)2$6,1432021
GENZYME CORPORATION2$3,7002021
Incyte Corporation17$2,3752021
Johnson & Johnson Health Care Systems Inc.48$1,6722021
Stryker Corporation1$162021

By nature of payment

NatureRecordsAmount
Research payment40$193,017
Debt forgiveness48$1,672
Long term medical supply or device loan1$16

Records

DateCompanyAmountNatureFormProductStudyYear
2021-12-31Stryker Corporation$16Long term medical supply or device loanIn-kind items and servicesSYSTEM 7 STRYKER PRECISION Device, SURGICAL2021
2021-10-13Gilead Sciences, Inc.$5,200Research paymentCash or cash equivalentVeklury Drug, COVID-19A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesi2021
2021-09-01Gilead Sciences, Inc.$3,550Research paymentCash or cash equivalentVeklury Drug, COVID-19A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesi2021
2021-09-01Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$1,713Research paymentCash or cash equivalentA Prospective, Long-Term Registry of Patients with a Diagnosis of Spinal Muscular Atrophy2021
2021-08-26Johnson & Johnson Health Care Systems Inc.$5Debt forgivenessIn-kind items and services2021
2021-08-26Johnson & Johnson Health Care Systems Inc.$4Debt forgivenessIn-kind items and services2021
2021-08-09Incyte Corporation$49Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2021
2021-08-09Incyte Corporation$42Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2021
2021-08-09Incyte Corporation$24Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2021
2021-08-09Incyte Corporation$20Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2021
2021-08-09Incyte Corporation$12Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2021
2021-08-09Incyte Corporation$0Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2021
2021-08-05Abbott Laboratories$2,000Research paymentCash or cash equivalentMitraClip System Device, Structural Heart15mm Surgical Mechanical Aortic Valve PAS2021
2021-08-05Abbott Laboratories$1,000Research paymentCash or cash equivalentMitraClip System Device, Structural Heart15mm Surgical Mechanical Aortic Valve PAS2021
2021-08-02Johnson & Johnson Health Care Systems Inc.$0Debt forgivenessIn-kind items and services2021
2021-07-28Abbott Laboratories$1,216Research paymentCash or cash equivalentMitraClip System Device, Structural Heart15mm Surgical Mechanical Aortic Valve PAS2021
2021-07-28Abbott Laboratories$40Research paymentCash or cash equivalentMitraClip System Device, Structural Heart15mm Surgical Mechanical Aortic Valve PAS2021
2021-06-22Johnson & Johnson Health Care Systems Inc.$156Debt forgivenessIn-kind items and services2021
2021-06-22Johnson & Johnson Health Care Systems Inc.$2Debt forgivenessIn-kind items and services2021
2021-06-21Johnson & Johnson Health Care Systems Inc.$76Debt forgivenessIn-kind items and services2021
2021-06-11Incyte Corporation$1,000Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2021
2021-06-11Incyte Corporation$1,000Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2021
2021-06-08Incyte Corporation$49Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2021
2021-06-08Incyte Corporation$24Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2021
2021-06-08Incyte Corporation$21Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2021
2021-06-08Incyte Corporation$12Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2021
2021-06-08Incyte Corporation$10Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2021
2021-05-20Johnson & Johnson Health Care Systems Inc.$17Debt forgivenessIn-kind items and services2021
2021-05-20Johnson & Johnson Health Care Systems Inc.$15Debt forgivenessIn-kind items and services2021
2021-05-13Johnson & Johnson Health Care Systems Inc.$31Debt forgivenessIn-kind items and services2021
2021-05-13Johnson & Johnson Health Care Systems Inc.$8Debt forgivenessIn-kind items and services2021
2021-05-12Gilead Sciences, Inc.$18,775Research paymentCash or cash equivalentVeklury Drug, COVID-19A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesi2021
2021-05-04GENZYME CORPORATION$2,200Research paymentCash or cash equivalentHECTOROL Drug, Genetic DiseaseAn Open-Label, Randomized, Parallel Group Study to Assess the Safety and Efficacy of Hectorol (Doxercalciferol Capsules)2021
2021-05-04Johnson & Johnson Health Care Systems Inc.$51Debt forgivenessIn-kind items and services2021
2021-05-04Johnson & Johnson Health Care Systems Inc.$14Debt forgivenessIn-kind items and services2021
2021-04-28Gilead Sciences, Inc.$2,825Research paymentCash or cash equivalentVeklury Drug, COVID-19A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesi2021
2021-04-28Johnson & Johnson Health Care Systems Inc.$34Debt forgivenessIn-kind items and services2021
2021-04-28Johnson & Johnson Health Care Systems Inc.$6Debt forgivenessIn-kind items and services2021
2021-04-23Novo Nordisk AS$3,500Research paymentCash or cash equivalentNN8640-42632021
2021-04-23Novo Nordisk AS$2,000Research paymentCash or cash equivalentNN8640-42632021
2021-04-23Novo Nordisk AS$1,000Research paymentCash or cash equivalentNN8640-42632021
2021-04-23Novo Nordisk AS$645Research paymentCash or cash equivalentNN8640-42632021
2021-04-21Johnson & Johnson Health Care Systems Inc.$24Debt forgivenessIn-kind items and services2021
2021-04-21Johnson & Johnson Health Care Systems Inc.$5Debt forgivenessIn-kind items and services2021
2021-04-19Johnson & Johnson Health Care Systems Inc.$3Debt forgivenessIn-kind items and services2021
2021-04-19Johnson & Johnson Health Care Systems Inc.$1Debt forgivenessIn-kind items and services2021
2021-04-14Abbott Laboratories$4,033Research paymentCash or cash equivalentXience Sierra Coronary Stent Device, Vascular15mm Surgical Mechanical Aortic Valve PAS2021
2021-04-07PFIZER INC.$3,314Research paymentCash or cash equivalentA RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG2021
2021-04-06Johnson & Johnson Health Care Systems Inc.$3Debt forgivenessIn-kind items and services2021
2021-04-06Johnson & Johnson Health Care Systems Inc.$3Debt forgivenessIn-kind items and services2021
2021-03-31Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$4,430Research paymentCash or cash equivalentA Prospective, Long-Term Registry of Patients with a Diagnosis of Spinal Muscular Atrophy2021
2021-03-30Johnson & Johnson Health Care Systems Inc.$26Debt forgivenessIn-kind items and services2021
2021-03-30Johnson & Johnson Health Care Systems Inc.$25Debt forgivenessIn-kind items and services2021
2021-03-24PFIZER INC.$16,100Research paymentCash or cash equivalentA RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG2021
2021-03-24PFIZER INC.$170Research paymentCash or cash equivalentA RANDOMIZED OPEN LABEL ACTIVE CONTROLLED SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAG2021
2021-03-24Johnson & Johnson Health Care Systems Inc.$16Debt forgivenessIn-kind items and services2021
2021-03-24Johnson & Johnson Health Care Systems Inc.$0Debt forgivenessIn-kind items and services2021
2021-03-17Gilead Sciences, Inc.$2,103Research paymentCash or cash equivalentVeklury Drug, COVID-19A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesi2021
2021-03-17Johnson & Johnson Health Care Systems Inc.$895Debt forgivenessIn-kind items and services2021
2021-03-17Johnson & Johnson Health Care Systems Inc.$5Debt forgivenessIn-kind items and services2021
2021-03-17Johnson & Johnson Health Care Systems Inc.$1Debt forgivenessIn-kind items and services2021
2021-03-11Johnson & Johnson Health Care Systems Inc.$5Debt forgivenessIn-kind items and services2021
2021-03-11Johnson & Johnson Health Care Systems Inc.$3Debt forgivenessIn-kind items and services2021
2021-03-03Johnson & Johnson Health Care Systems Inc.$4Debt forgivenessIn-kind items and services2021
2021-03-03Johnson & Johnson Health Care Systems Inc.$1Debt forgivenessIn-kind items and services2021
2021-03-01Johnson & Johnson Health Care Systems Inc.$38Debt forgivenessIn-kind items and services2021
2021-02-23Johnson & Johnson Health Care Systems Inc.$13Debt forgivenessIn-kind items and services2021
2021-02-23Johnson & Johnson Health Care Systems Inc.$4Debt forgivenessIn-kind items and services2021
2021-02-17Gilead Sciences, Inc.$26,772Research paymentCash or cash equivalentVeklury Drug, COVID-19A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesi2021
2021-02-16Johnson & Johnson Health Care Systems Inc.$20Debt forgivenessIn-kind items and services2021
2021-02-16Johnson & Johnson Health Care Systems Inc.$4Debt forgivenessIn-kind items and services2021
2021-02-11Johnson & Johnson Health Care Systems Inc.$0Debt forgivenessIn-kind items and services2021
2021-02-05Johnson & Johnson Health Care Systems Inc.$0Debt forgivenessIn-kind items and services2021
2021-01-28Johnson & Johnson Health Care Systems Inc.$22Debt forgivenessIn-kind items and services2021
2021-01-28Johnson & Johnson Health Care Systems Inc.$6Debt forgivenessIn-kind items and services2021
2021-01-25GENZYME CORPORATION$1,500Research paymentCash or cash equivalentHECTOROL Drug, Genetic DiseaseAn Open-Label, Randomized, Parallel Group Study to Assess the Safety and Efficacy of Hectorol (Doxercalciferol Capsules)2021
2021-01-21Johnson & Johnson Health Care Systems Inc.$2Debt forgivenessIn-kind items and services2021
2021-01-21Johnson & Johnson Health Care Systems Inc.$1Debt forgivenessIn-kind items and services2021
2021-01-13Johnson & Johnson Health Care Systems Inc.$11Debt forgivenessIn-kind items and services2021
2021-01-13Johnson & Johnson Health Care Systems Inc.$0Debt forgivenessIn-kind items and services2021
2021-01-11Incyte Corporation$49Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2021
2021-01-11Incyte Corporation$24Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2021
2021-01-11Incyte Corporation$21Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2021
2021-01-11Incyte Corporation$12Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2021
2021-01-08Johnson & Johnson Health Care Systems Inc.$40Debt forgivenessIn-kind items and services2021
2021-01-08Johnson & Johnson Health Care Systems Inc.$11Debt forgivenessIn-kind items and services2021
2021-01-04Johnson & Johnson Health Care Systems Inc.$26Debt forgivenessIn-kind items and services2021
2021-01-04Johnson & Johnson Health Care Systems Inc.$16Debt forgivenessIn-kind items and services2021
2021-01-01VERTEX PHARMACEUTICALS INCORPORATED$86,554Research paymentCash or cash equivalentA Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy2021

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Madera CountyMadera city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Madera, CA, county Madera County, CA, state California; placed by its city name.

MeasurePlace (city or town)
Madera, CA
County
Madera County, CA
State
California
Population B0100367,831160,94039,287,377
Population, 2020 census P166,224156,25539,538,223
Median age B0100230.434.637.9
Under 18 B0100130.8%27.1%22.0%
65 and over B010019.6%14.4%15.7%
Households B1100117,52645,37913,548,091
Foreign born B0500225.6%20.1%27.0%
Median household income B19013$63,933$76,627$99,122
Median family income B19113$67,479$83,389$113,346
Per capita income B19301$24,200$30,077$49,513
Poverty rate B1700125.6%19.2%12.0%
Unemployment rate B2302512.6%10.1%6.6%
Civilian labor force B2302529,99769,01220,068,466
Mean commute (minutes) B0801325.727.928.7
Bachelor's degree or higher B1500310.9%17.9%37.1%
Housing units B2500118,56251,01514,644,735
Owner-occupied B2500354.7%67.5%55.9%
Renters B2500345.3%32.5%44.1%
Median home value B25077$359,900$393,200$734,700
Median gross rent B25064$1,353$1,390$2,036
White, not Hispanic B0300212.2%29.9%33.8%
Black B030022.9%2.4%5.2%
Hispanic or Latino B0300281.1%60.9%40.2%
Asian B030021.3%2.4%15.3%
American Indian and Alaska Native B030020.1%0.4%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.1% in Sep 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Madera, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.